The WATER (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) II Study is a prospective, single-arm U.S. investigational device exemption (IDE) clinical trial evaluating the safety and effectiveness of the AquaBeam System and Aquablation in large prostates (80 to 150 grams). The study will enroll 100 men from up to 15 sites in the United States and 3 sites from Canada. Protocol details and participating centers can be found at here. A patient brochure providing more details about the study can be found here.

The initial results from the WATER Study (prostates size 30 to 80 grams) were presented at the American Urological Association (AUA) Annual Meeting in Boston, on May 14, 2017.

View the presentation here.

View the press release here.